Search Results - "Chudej, Juraj"

Ixazomib, lenalidomide, and dexamethasone combination in “real-world” clinical practice in patients with relapsed/refractory multiple myeloma by Sokol, Juraj, Guman, Tomas, Chudej, Juraj, Hlebaskova, Monika, Stecova, Natalia, Valekova, Lubica, Kucerikova, Monika, Stasko, Jan

“…Ixazomib is approved for use in combination with lenalidomide and dexamethasone (IRd) for patients with multiple myeloma (MM) who received at least one…”
Get full text

Paroxysmal nocturnal hemoglobinuria: A rare case of recurrent episodes of icterus by Hoferica Jakub, Nosakova Lenka, Uhrik, Peter, Vazanova Diana, Matus, Scur, Chudej Juraj, Banovcin, Peter

“…In this work we describe a rare case of a patient with paroxysmal nocturnal hemoglobinuria (PNH) developed on the background of specific medical history of…”
Get full text

Evaluation of 5‐year imatinib treatment of 458 patients with CP‐CML in routine clinical practice and prognostic impact of different BCR‐ABL cutoff levels by Klamová, Hana, Poláková, Kateřina Machová, Mužík, Jan, Ráčil, Zdeněk, Žáčková, Daniela, Steinerová, Kateřina, Karas, Michal, Faber, Edgar, Demečková, Eva, Michalovičová‐Sninská, Zuzana, Voglová, Jaroslava, Demitrovičová, Ľudmila, Mikušková, Eva, Tóthová, Elena, Chudej, Juraj, Markuljak, Imrich, Cmunt, Eduard, Moravcová, Jana, Dvořáková, Dana, Michalová, Kyra, Jarošová, Marie, Šťastná, Markéta Marková, Cetkovský, Petr, DuŠek, Ladislav, Koza, Vladimír, Trněný, Marek, Indrák, Karel

“…We evaluated responses to the treatment and long‐term outcomes of chronic myeloid leukemia patients treated with imatinib as first‐line treatment in routine…”
Get full text

in vitro testing of chemoresistance in leukaemic patients by Hatok, Jozef, Tatiana MatákovÃ, Juraj Chudej, Ján StaÅ¡ko, Miroslava DobrotovÃ, DuÅ¡an Dobrota, Peter Račay

“…The fact that leukaemic cells are primarily or secondarily resistant to cytostatics is a serious phenomenon, which leads to the failure of chemotherapy of…”
Get full text

Prothrombin gene 20210A mutation in Slovak population by Chudej, Juraj, Plameňová, Ivana

“…Factor V Leiden (FVL) and prothrombin G20210A mutation (PTM) are the two most common genetic polymorphisms known to predispose to a first episode of venous…”
Get more information

Treatment Outcomes in Patients Treated with Tyrosine Kinase Inhibitors in "Slovak Registry of Chronic Myeloid Leukemia" (CAMELIA SK) by Sninska, Zuzana, Mistrik, Martin, Slezakova, Katarina, Demitrovicova, Ludmila, Mikuskova, Eva, Markuljak, Imrich, Chudej, Juraj, Stecova, Natalia, Tothova, Elena, Kafkova, Adriana, Palasthy, Stanislav, Lesko-Andrascikova, Jana, Necasova, Tereza, Koritakova, Eva

“…Introduction: With the onset of tyrosine kinase inhibitors (TKI) to treat patients with CML, the number of patients and overall survival increased and quality…”
Get full text

Inherited thrombophilia in a patient with colorectal carcinoma by Hrnčár, Matej, Breznický, Jozef, Chudej, Juraj, Sokol, Juraj, Staško, Ján

Get full text

Heparin induced thrombocytopenia and up to date options of treatment - review of literature by Sokol, Juraj, Nehaj, František, Chudej, Juraj, Mokáň, Michal, Kubašková, Marianna, Péč, Martin Jozef, Žolková, Jana, Vadelová, Ubica, Galajda, Peter, Staško, Ján

“…Heparin-induced thrombocytopenia (HIT) is a profoundly dangerous, potentially lethal, immunologically mediated adverse drug reaction to unfractionated heparin…”
Get more information

Endovascular stenting in malignant obstruction of superior vena cava by Hamzik, Julian, Chudej, Juraj, Dzian, Anton, Sokol, Juraj, Kubisz, Peter

“…Highlights • Lymphomas are a common cause of SVCS in young age. • HL may present as SVCS. • Pathological confirmation of diagnosis should be done before…”
Get full text

Treatment of Consecutive Patients with Chronic Myeloid Leukemia In the Cooperating Centers From the Slovak Republic After 2000 – A Report From the Population Based CAMELIA Registry by Demeckova, Eva, Mistrik, Martin, Demitrovicova, Ludmila, Chudej, Juraj, Markuliak, Imrich, Tothova, Elena, Muzik, Jan, Dusek, Ladislav

“…Abstract 4439 Most results on the treatment of chronic myeloid leukemia (CML) with imatinib were obtained from clinical trials that may differ from the routine…”
Get full text

C0173 High levels of von Willebrand factor antigen and procoagulant factor VIII found in multiple myeloma patients are associated with activity status by Sokol, Juraj, Flochová, Emília, Chudej, Juraj, Šimonová, Radoslava, Chudá, Daniela, Chudý, Peter, Staško, Ján, Kubisz, Peter

Get full text

Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry by Faber, Edgar, Mužík, Jan, Koza, Vladimír, Demečková, Eva, Voglová, Jaroslava, Demitrovičová, Ĺudmila, Chudej, Juraj, Markuljak, Imrich, Cmunt, Eduard, Kozák, Tomáš, Tóthová, Elena, Jarošová, Marie, Dušek, Ladislav, Indrák, Karel

“…Background: Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib were obtained from clinical trials that may differ from the routine…”
Get full text

Differential impact of bortezomib on HL-60 and K562 cells by Kliková, Katarína, Štefaniková, Andrea, Pilchová, Ivana, Hatok, Jozef, Chudý, Peter, Chudej, Juraj, Dobrota, Dušan, Račay, Peter

“…Bortezomib (PS-341, or Velcade), reversible inhibitor of 20S proteasome approved for the treatment of multiple myeloma and mantle cell lymphoma, exhibited a…”
Get more information

Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications by Pavlik, Tomas, Janousova, Eva, Mayer, Jiri, Indrak, Karel, Jarosova, Marie, Klamova, Hana, Zackova, Daniela, Voglova, Jaroslava, Faber, Edgar, Karas, Michal, Machova Polakova, Katerina, Racil, Zdenek, Demeckova, Eva, Demitrovicova, Ludmila, Tothova, Elena, Chudej, Juraj, Markuljak, Imrich, Cmunt, Eduard, Kozak, Tomas, Muzik, Jan, Dusek, Ladislav

“…Using the data of 723 chronic myeloid leukemia (CML) patients in the chronic phase, we analyzed the prognostic value of the Sokal, Euro, and EUTOS scores as…”
Get full text

Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry: CAMELIA Registry report on CML treatment by Faber, Edgar, Mužík, Jan, Koza, Vladimír, Demečková, Eva, Voglová, Jaroslava, Demitrovičová, Ĺudmila, Chudej, Juraj, Markuljak, Imrich, Cmunt, Eduard, Kozák, Tomáš, Tóthová, Elena, Jarošová, Marie, Dušek, Ladislav, Indrák, Karel

Get full text

Transcription of genes of p53-dependent apoptosis in acute leukaemia by Racay, Peter, Hatok, Jozef, Hudecek, Jan, Chudej, Juraj, Jurecekova, Jana, Dobrota, Dusan

“…Tumour suppressor protein p53 prevents cancer development through various mechanisms, including the induction of apoptosis. We demonstrated that acute…”
Get full text

The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–2009 by Klamova, Hana, Zackova, Daniela, Faber, Edgar, Steinerova, Katerina, Karas, Michal, Demeckova, Eva, Voglova, Jaroslava, Demitrovicova, Ludmila, Tothova, Elena, Chudej, Juraj, Markuljak, Imrich, Kozak, Tomas, Cmunt, Eduard, Jarosova, Marie, Machova-Polakova, Katerina, Michalova, Kyra, Dusek, Ladislav, Muzik, Jan, Mistrik, Martin, Mayer, Jiri, Trneny, Marek, Indrak, Karel

“…Abstract 1239 Imatinib (IM), a selective BCR-ABL tyrosine kinase inhibitor (TKI), is a treatment of choice for newly diagnosed chronic myeloid leukemia (CML)…”
Get full text